Figure 3.

Acute vs. progressive diabetes onset in NOD mice affects ability to reverse disease with ATG + G-CSF combination therapy. Ability to reverse T1D with ATG + G-CSF combination therapy trended greater for animals with progressive T1D onset (P = 0.0815, χ² test) (A) and mild hyperglycemia (blood glucose <450 mg/dL) (P = 0.0653, χ² test) (B). C: Ability to reverse T1D with ATG + G-CSF combination therapy was significantly greater for animals with both progressive onset and diagnostic blood glucose <450 mg/dL at T1D onset (P < 0.05, χ² test). Data are presented as absolute number (percentage) of animals within each category (acute vs. progressive and/or blood glucose status) that reversed (gray bars) or failed (white bars) in response to combination immune therapy.